DeepHealth introduced a cloud-first integrated portfolio at ECR 2026 that unifies clinical AI, multi-modality viewing and reporting across MR, CT, X-ray, mammography and ultrasound. The launch follows the acquisition of Gleamer, positioning DeepHealth to advance screening tools into routine imaging and acute diagnostic care on a single platform.

The Breast Suite combines AI-powered detection, risk assessment, breast density analysis and new mammography analytics via Aquila integration, and adds supplemental ultrasound through See-Mode. A real-world study across 579,000 women showed a 21% boost in cancer detection, and the suite’s risk model achieves twice the accuracy of traditional predictors while also identifying cardiovascular risk via arterial calcification analysis.

Chest Suite applications automate pulmonary nodule detection, characterization and volumetric quantification with standardized reporting and longitudinal tracking. The suite supports NHS England’s Lung Cancer Screening program and France’s CASCADE study, demonstrating improved diagnostic accuracy, interobserver agreement and read efficiency in both routine and low-dose CT exams.

Neuro Suite automates quantification of key brain structures—including hippocampus, cortical lobes and subcortical regions—to enable early detection of neurodegenerative conditions. Demonstrating 92% sensitivity for hippocampal atrophy, the suite’s white matter hyperintensity algorithm provides expert-level biomarker data for risk stratification and longitudinal tracking.